BPG is committed to discovery and dissemination of knowledge
Cited by in CrossRef
For: Juneja D, Nasa P, Jain R, Singh O. Sodium-glucose Cotransporter-2 Inhibitors induced euglycemic diabetic ketoacidosis: A meta summary of case reports. World J Diabetes 2023; 14(8): 1314-1322 [PMID: 37664476 DOI: 10.4239/wjd.v14.i8.1314]
URL: https://www.wjgnet.com/1948-9358/full/v14/i8/1314.htm
Number Citing Articles
1
Alessandro Rossi, Chiara Simeoli, Rosario Pivonello, Mariacarolina Salerno, Carmen Rosano, Barbara Brunetti, Pietro Strisciuglio, Annamaria Colao, Giancarlo Parenti, Daniela Melis, Terry G.J. Derks. Endocrine involvement in hepatic glycogen storage diseases: pathophysiology and implications for careReviews in Endocrine and Metabolic Disorders 2024; 25(4): 707 doi: 10.1007/s11154-024-09880-2
2
Swapnil Khare, Mihail Zilbermint, Rajesh Garg, Viral N. Shah. Navigating the New Frontiers of Hyperglycemic Crisis Management: Unveiling the Latest American Diabetes Association Consensus ReportEndocrine Practice 2024; 30(9): 895 doi: 10.1016/j.eprac.2024.06.011
3
Lulu Chu, Zhenhua Xi, Runzhi Ma, Weiliang Shi, Guoshen Yu. Euglycemic diabetic ketoacidosis associated metabolic encephalopathy caused by dapagliflozin: a rare case reportBMC Neurology 2025; 25(1) doi: 10.1186/s12883-025-04027-5
4
Dimitra Stathi, Ketan K. Dhatariya, Omar G. Mustafa. Management of diabetes‐related hyperglycaemic emergencies in advanced chronic kidney disease: Review of the literature and recommendationsDiabetic Medicine 2025; 42(2) doi: 10.1111/dme.15405
5
Andreas Holstein, Jonas A. Linck, Johann Christoph Blaue, Rainer Högel, David J. F. Holstein. Successful renal replacement therapy of extreme ertugliflozin and alcohol induced euglycaemic ketoacidosisActa Diabetologica 2024;  doi: 10.1007/s00592-024-02417-8
6
Andrijana Koceva, Nika Aleksandra Kravos Tramšek. From Sweet to Sour: SGLT-2-Inhibitor-Induced Euglycemic Diabetic KetoacidosisJournal of Personalized Medicine 2024; 14(7): 665 doi: 10.3390/jpm14070665
7
Rohini Garg, Nikhil Sood, Ojas Bansal, Abhinav Hoskote. Euglycemic Ketoacidosis Associated with SGLT-2 Inhibitors in Non-diabetic Patients—A Narrative ReviewJournal of General Internal Medicine 2024;  doi: 10.1007/s11606-024-09073-2
8
Selin Genc, Bahri Evren, Onur Selcuk Yigit, Ibrahim Sahin, Ramazan Dayanan, Aleksandra Klisic, Ayse Erturk, Filiz Mercantepe. Evolving Clinical Features of Diabetic Ketoacidosis: The Impact of SGLT2 InhibitorsPharmaceuticals 2024; 17(11): 1553 doi: 10.3390/ph17111553
9
Afif Nakhleh, Areen Othman, Amin Masri, Moshe Zloczower, Sagit Zolotov, Naim Shehadeh. Clinical Outcomes of Diabetic Ketoacidosis in Type 2 Diabetes Patients with and without SGLT2 Inhibitor Treatment: A Retrospective StudyBiomedicines 2023; 11(10): 2689 doi: 10.3390/biomedicines11102689
10
Paul A. Stewart, Claire C. Nestor, Cillian Clancy, Michael G. Irwin. The peri‐operative implications of sodium‐glucose co‐transporter 2 inhibitors: a narrative reviewAnaesthesia 2025; 80(1): 85 doi: 10.1111/anae.16461